| piclidenoson (CF101) / Can-Fite |
NCT06643260: A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy |
|
|
| Not yet recruiting | 3 | 705 | NA | piclidenoson, Placebo | Can-Fite BioPharma | Plaque Psoriasis | 12/27 | 06/28 | | |
2021-002009-85: Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Pilot Trial Пиклиденозон за лечение на COVID-19 – Рандомизирано, двойно-заслепено, плацебо-контролирано пилотно изпитване. |
|
|
| Not yet recruiting | 2 | 100 | Europe | Piclidenoson, CF101, Tablet | Can-Fite BioPharma, Ltd., CanFite BioPharma Ltd. | COVID-19 КОВИД-19, COVID-19 КОВИД-19, Diseases [C] - Virus Diseases [C02] | | | | |
| namodenoson (CF102) / Can-Fite |
2021-005286-41: Clinical trial in patients with Advanced Hepatocellular Carcinoma and Child Pugh Class B7 cirrhosis. Клинично изпитване при пациенти с с авансирал хепатоцелуларен карцином с Child-Pugh цироза клас Б7 |
|
|
| Ongoing | 3 | 471 | Europe | CF102, CF102, Capsule | CanFite BioPharma Ltd., CanFite BioPharma Ltd. | Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis Авансирал хепатоцелуларен карцином с Child-Pugh цироза клас В7, Liver cancer Чернодробен карцином, Diseases [C] - Cancer [C04] | | | | |
LIVERATION, NCT05201404: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis |
|
|
| Recruiting | 3 | 471 | Europe, US, RoW | Namodenoson, CF102, Placebo, Inactive control | Can-Fite BioPharma | Hepatocellular Carcinoma, Cirrhosis | 02/25 | 10/25 | | |
| Not yet recruiting | 2 | 20 | RoW | Namodenoson 25mg, CF102 | Can-Fite BioPharma | Pancreatic Adenocarcinoma, Pancreatic Cancer | 07/26 | 12/26 | | |
| Recruiting | 2 | 114 | Europe, RoW | Namodenoson, CF102, Placebo, Inactive control | Can-Fite BioPharma, CanFite BioPharma Ltd. | NASH - Nonalcoholic Steatohepatitis | 04/25 | 10/25 | | |
| CF602 / Can-Fite |
| No trials found |
